Huma Therapeutics has raised 拢92 million to scale its modular platform for powering digital 鈥榟ospitals at home鈥� nationally.
A further commitment of 拢50m that can be exercised听at a later date听has also been agreed as part of the Series C funding round and takes the total financing raised to almost 拢150m.听
Leaps by Bayer and Hitachi Ventures led the Series C funding round, which also saw new strategic and financial investors become shareholders.听听
Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.听
The new investment will听also听be used to expand Huma鈥檚 digital platform in the US, Asia and the Middle East, with Huma having recently been named Europe鈥檚 fastest growing healthcare company by the Financial Times.听听
It will also听support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma鈥檚 platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.听
/ar-start-up-wins-grant-to-transform-hospital-construction/
Huma听is听an听innovation partner to four national governments听–听England鈥檚 NHS, Wales, Germany and UAE听鈥� and its听digital 鈥榟ospital at home鈥� was co-created with clinicians and has been independently shown to almost double clinical capacity, reduce hospital readmissions by over a third and has patient adherence levels of over 90%.听听
The service is supporting governments鈥� pandemic responses on a not-for-profit basis and is now used for a range of patients including those going through knee- and hip-replacement surgery.听
Huma advanced its work in the US in 2021 with an experienced leadership team that has fostered new partnerships with clinical research organisations, health care providers, payers, research organisations, and technology companies.听
Huma works with leading life science companies including AstraZeneca, Bayer and Janssen and academic institutions such as Stanford Medicine, the Johns Hopkins Bloomberg School of Public Health and the University of Cambridge.听听
鈥淭his is a pivotal moment in Huma鈥檚 development,鈥� said founder and CEO听Dan Vahdat. 鈥淲e have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives.听听
鈥淲e鈥檙e already demonstrating how 鈥榟ospital at home鈥� can transform healthcare, and how decentralised clinical trials can advance research in ways that weren鈥檛 imaginable even one year ago.听
鈥淣ow we want to accelerate the pace of change and continue to innovate for better care and research worldwide.鈥欌��听
/device-to-take-guesswork-out-of-knee-operations/
Alan Milburn, former UK Health Secretary and Chairman of Huma鈥檚 Board, said:听鈥淭his is a significant moment in Huma鈥檚听history听and I will work to build enduring, trusted relationships with our new partners.听听
鈥�We are living through unprecedented times and the importance of health and well-being is underlined as never before. Together with our partners we can use our expertise, technology, and innovation to change the face of healthcare and research and impact people鈥檚 health everywhere.鈥�听
Dr Claudia Suessmuth Dyckerhoff, Huma Board Director, said: 鈥淭he pandemic has exposed weaknesses across health systems around the world but through collaboration, innovation, and compassionate leadership Huma can support faster and safer care for patients through digital technologies and rapid access to treatments by accelerating clinical research.鈥�听